Home  /  Resource Library  /  First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma

First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma

Results of a study investigating epcoritamab combined with rituximab and bendamustine for first line treatment of follicular lymphoma.